MAPS Attends Historic FDA Hearing on Psychedelics

Washington, D.C., September 17, 2026 — The FDA’s September 14 hearing marked one of the most consequential regulatory moments for psychedelic-assisted therapy to date. The Multidisciplinary Association for Psychedelic Studies (MAPS) attended, and plans to submit formal, written testimony to the FDA’s public docket on systems readiness, therapist training, and patient access. MAPS also shared… Continue reading MAPS Attends Historic FDA Hearing on Psychedelics